SAB Biotherapeutics, Inc.
SABS
$1.79
$0.03992.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 19.17% | -67.46% | -38.15% | -47.21% | -125.14% |
| Total Depreciation and Amortization | 27.96% | 32.94% | 36.20% | 35.88% | 13.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -124.36% | 21.81% | 33.76% | 2,924.65% | 241.55% |
| Change in Net Operating Assets | -198.83% | -111.09% | -158.81% | -156.76% | 1,079.04% |
| Cash from Operations | -36.52% | -188.84% | -132.07% | -120.67% | -7.08% |
| Capital Expenditure | -71.04% | -41.56% | -39.33% | 63.27% | 90.90% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -41.75% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -7,728.66% | -10,438.18% | -8,326.63% | -3,692.23% | 92.69% |
| Total Debt Issued | -32.57% | -38.10% | -38.10% | -38.10% | -38.10% |
| Total Debt Repaid | -23.13% | -2.76% | 39.70% | 47.37% | 52.27% |
| Issuance of Common Stock | -99.97% | 676.56% | 676.84% | 669.91% | 669.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -101.76% | 780.53% | 805.29% | 852.10% | 6,250.88% |
| Foreign Exchange rate Adjustments | -1,432.60% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -214.81% | 214.20% | 207.08% | 110.42% | 269.48% |